ClinicalTrials.gg
Active, not recruitingNCT04637763Updated Oct 19, 2026

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

A Phase 1 interventional study of CB-010 and Cyclophosphamide in Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma and Refractory B-Cell Non-Hodgkin Lymphoma, sponsored by Caribou Biosciences, Inc.. Active, not recruiting at 38 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Primary conditionLymphoma, B-CellRegistry: Lymphoma, Non-HodgkinReclassifiedWhy we changed it
Registry
Lymphoma, Non-Hodgkin — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, B-Cell
Why
  1. The study's listed conditions name Lymphoma, B-Cell, a narrower term within Lymphoma, Non-Hodgkin.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Caribou Biosciences, Inc. · Phase 1, Interventional, and Treatment

Updated Oct 19, 2026Now Active, not recruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing cyclophosphamide in Lymphoma, B-Cell — 8 open to participants now, 12 under way, none of them phase 3. Cyclophosphamide · Lymphoma, B-Cell.

Planned enrollment
9th of 32
72 · median 37
Started
2021
with 4 others
Phase 1
7 of 32
2 open now
Primary completion
2025-09
later than 3 of 11 live
Registered
22nd of 32
by date
Lead sponsor
1 of 32
Caribou Biosciences, Inc.

Among the 32 studies testing cyclophosphamide in Lymphoma, B-Cell, this one is the 9th largest by planned enrollment, is one of 5 that started in 2021, is one of 7 in phase 1, reaches primary completion later than 3 of the 11 other live ones, and was the 22nd registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

8 of the 32 studies testing cyclophosphamide in Lymphoma, B-Cell are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing cyclophosphamide in Lymphoma, B-Cell, or all of them as a file.
02

Study summary

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.

Read the detailed description

This clinical trial is a first-in-human, Phase 1, multicenter, open-label evaluation of safety and emerging efficacy of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma. The study is conducted in two parts: Part A is dose escalation following a 3 + 3 design, with sequential, prespecified, increasing doses. Part B is the expansion portion where patients will receive CB-010 at the dose determined in Part A.

03

Conditions studied

  • Lymphoma, Non-Hodgkin
  • Relapsed Non Hodgkin Lymphoma
  • Refractory B-Cell Non-Hodgkin Lymphoma
  • Non Hodgkin Lymphoma
  • Lymphoma
  • B Cell Lymphoma
  • B Cell Non-Hodgkin's Lymphoma

Browse trials for

04

In context

Lymphoma, B-Cell Reclassified

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

This study's planned enrollment of 72 is above the median of 34 across 773 interventional studies indexed under Lymphoma, B-Cell.

Browse Lymphoma, B-Cell studies →

Lead sponsor

Caribou Biosciences, Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Compared within Lymphoma, B-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, Non-Hodgkin. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age greater than or equal to 18 at the time of enrollment
  • Documented diagnosis of non-Hodgkin lymphoma after prior standard of care
  • performance status 0 or 1
  • Adequate hematologic, renal, liver, cardiac and pulmonary organ function

Exclusion criteria

Exclusion Criteria:

  • Prior therapy with an anti-CD19 targeting agent
  • Active or chronic requiring therapy
  • Prior stem cell transplantation
  • Central nervous system (CNS) lymphoma, prior CNS
  • Prior seizure disorder, cerebrovascular ischemia, dementia, cerebellar disease or disease with CNS involvement.
  • Primary immunodeficiency
  • Current or expected need for systemic therapy
  • Current thyroid disorder. Hypothyroidism controlled with stable hormone replacement is permitted
  • Other malignancy within 2 years of study entry, except curatively treated malignancies or malignancies with low risk of recurrence
  • Unwillingness to follow extended safety monitoring
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Dose Escalation of CB-010

    Patients with relapsed or refractory non-Hodgkin lymphoma will receive CB-010 following lymphodepletion.

    Genetic: CB-010 · Drug: Cyclophosphamide · Drug: Fludarabine

  • Experimental
    Expansion of CB-010

    Patients with relapsed or refractory non-Hodgkin lymphoma will receive CB-010 following lymphodepletion.

    Genetic: CB-010 · Drug: Cyclophosphamide · Drug: Fludarabine

Interventions

  • GeneticCB-010

    CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19.

  • Chemotherapy for lymphodepletion

  • Chemotherapy for lymphodepletion

07

What researchers measure

Primary outcomes

  1. Primary outcome measures number of patients with dose-limiting toxicities (Part A).

    Incidence of adverse events defined as dose-limiting toxicities with onset within 28 days after CB-010 infusion.

    Time frame: 28 days following CB-010 infusion

  2. Primary outcome evaluates tumor response (Part B)

    The primary endpoint is objective response rate.

    Time frame: Up to 12 months

08

Study locations

38 sites
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Sep 2025, 51 months.

Of 90 industry-sponsored phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's 51 months is close to that.

Counting every sponsor, half of 207 studies reached it within 51 months; a quarter within 37 and three quarters within 78.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Aug 2025 → Sep 2025 and completion Sep 2025 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2020
First posted
Nov 20, 2020
StartActual
May 26, 2021
Primary completionActual
Sep 11, 2025was Aug 2025
CompletionEst.
Dec 31, 2026was Sep 2025
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 19, 2026
Sites
11 sites added, 11 sites removed
Show 11 added (8 United States, 3 Israel)
  • Augusta University/Georgia Cancer Center · Augusta, United States
  • University of Iowa Hospitals & Clinics · Iowa City, United States
  • University of Kentucky · Lexington, United States
  • Regional Cancer Care Associates LLC - Hackensack · Hackensack, United States
  • NYU Langone Health · New York, United States
  • Montefiore Medical Center · New York, United States
  • Ohio State University Medical Group · Columbus, United States
  • Oregon Health & Science University (OHSU) · Portland, United States
  • The Tel Aviv Sourasky Medical Center · Tel Aviv, Israel
  • Rabin Medical Center - Beilinson Hospital · Petah Tikva, Israel
  • The Sheba Fund for Health Services and Research (R.A.) · Tel Litwinsky, Israel
Show 11 removed
  • Georgia Cancer Center at Augusta University · Augusta, United States
  • Holden Comprehensive Cancer Center at the University of Iowa · Iowa City, United States
  • University of Kentucky Markey Cancer · Lexington, United States
  • Hackensack Medical Center · Hackensack, United States
  • Montefiore Medical Center · Bronx, United States
  • Nyu Langone Health · New York, United States
  • Ohio State University James Cancer Hospital · Columbus, United States
  • Oregon Health & Science University · Portland, United States
  • Rabin Medical Center · Petah Tikva, Israel
  • Tel Aviv Medical Center · Tel Aviv, Israel
  • The Sheba Fund for Health Services and Research (R.A.) · Tel HaShomer, Israel
Oct 19, 2026
Primary completion
Aug 2025→Sep 11, 2025 (actual)
Oct 19, 2026
Study completion
Sep 2025→Dec 31, 2026
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Recruiting→Active, not recruiting
    11 sites added, 11 sites removed
    Show 11 added (8 United States, 3 Israel)
    • Augusta University/Georgia Cancer Center · Augusta, United States
    • University of Iowa Hospitals & Clinics · Iowa City, United States
    • University of Kentucky · Lexington, United States
    • Regional Cancer Care Associates LLC - Hackensack · Hackensack, United States
    • NYU Langone Health · New York, United States
    • Montefiore Medical Center · New York, United States
    • Ohio State University Medical Group · Columbus, United States
    • Oregon Health & Science University (OHSU) · Portland, United States
    • The Tel Aviv Sourasky Medical Center · Tel Aviv, Israel
    • Rabin Medical Center - Beilinson Hospital · Petah Tikva, Israel
    • The Sheba Fund for Health Services and Research (R.A.) · Tel Litwinsky, Israel
    Show 11 removed
    • Georgia Cancer Center at Augusta University · Augusta, United States
    • Holden Comprehensive Cancer Center at the University of Iowa · Iowa City, United States
    • University of Kentucky Markey Cancer · Lexington, United States
    • Hackensack Medical Center · Hackensack, United States
    • Montefiore Medical Center · Bronx, United States
    • Nyu Langone Health · New York, United States
    • Ohio State University James Cancer Hospital · Columbus, United States
    • Oregon Health & Science University · Portland, United States
    • Rabin Medical Center · Petah Tikva, Israel
    • Tel Aviv Medical Center · Tel Aviv, Israel
    • The Sheba Fund for Health Services and Research (R.A.) · Tel HaShomer, Israel
    Primary completion Aug 2025→Sep 11, 2025 (now actual)
    Study completion Sep 2025→Dec 31, 2026
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04637763
Lead sponsor
Caribou Biosciences, Inc.
Responsible party
Sponsor
First posted
Nov 20, 2020
Start date
May 26, 2021
Primary completion
Sep 11, 2025
Completion
Dec 31, 2026 (estimated)
Last update
Oct 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · Fludarabine

Start the discussion